Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study)

Plain-language summary

This study examines autoantibodies against type I interferon in patients with Ph-negative myeloproliferative neoplasms. People diagnosed with PV, ET, prePMF, overt PMF or MPN-U according to the 2016 WHO criteria who can provide a blood sample may take part. The study does not use a clinical phase and is active but not currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Start date

5/6/2022

Estimated completion

12/31/2030

Countries

Italy

Related genes

Locations

• Pavia, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* A diagnosis of PV, ET, prePMF, overt PMF or MPN-U according to 2016 WHO criteria
* Characterization of the MPN driver mutation performed at any moment before enrolment
* A peripheral blood (PB) sample collected at the enrolment visit suitable for plasma extraction and functional evaluation of anti-cytokine auto-Abs

Exclusion Criteria:

* None